These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 24605977)

  • 1. Designing multiregional trials under the discrete random effects model.
    Lan KK; Pinheiro J; Chen F
    J Biopharm Stat; 2014; 24(2):415-28. PubMed ID: 24605977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and evaluation of multiregional trials with heterogeneous treatment effect across regions.
    Chen CT; Hung HM; Hsiao CF
    J Biopharm Stat; 2012 Sep; 22(5):1037-50. PubMed ID: 22946948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and analysis issues of multiregional clinical trials with different regional primary endpoints.
    Tsou HH; Tsong Y; Chang WJ; Dong X; Hsiao CF
    J Biopharm Stat; 2012 Sep; 22(5):1051-9. PubMed ID: 22946949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Qualitative consistency of treatment effects in multiregional clinical trials.
    Tanaka Y; Li G; Wang Y; Chen J
    J Biopharm Stat; 2012 Sep; 22(5):988-1000. PubMed ID: 22946945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hierarchical dynamic allocation procedures based on modified Zelen's approach in multiregional studies with unequal allocation.
    Kuznetsova OM; Tymofyeyev Y
    J Biopharm Stat; 2014; 24(4):785-801. PubMed ID: 24697592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Introduction to randomized trials: the choice of endpoint].
    Simon EG; Fouché CJ; Perrotin F
    Gynecol Obstet Fertil; 2011 Oct; 39(10):595-6. PubMed ID: 21924939
    [No Abstract]   [Full Text] [Related]  

  • 7. Statistical considerations on design and analysis of bridging and multiregional clinical trials.
    Tsong Y
    J Biopharm Stat; 2012 Sep; 22(5):1078-80. PubMed ID: 22946952
    [No Abstract]   [Full Text] [Related]  

  • 8. Sample size estimation of multiregional clinical trials with heterogeneous variability across regions.
    Wu YJ; Tan TS; Chow SC; Hsiao CF
    J Biopharm Stat; 2014; 24(2):254-71. PubMed ID: 24605968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Misspecification of Cox regression models with composite endpoints.
    Wu L; Cook RJ
    Stat Med; 2012 Dec; 31(28):3545-62. PubMed ID: 22736519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decision rules and associated sample size planning for regional approval utilizing multiregional clinical trials.
    Chen X; Lu N; Nair R; Xu Y; Kang C; Huang Q; Li N; Chen H
    J Biopharm Stat; 2012 Sep; 22(5):1001-18. PubMed ID: 22946946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guest editors' note for the special issue on the statistical considerations for the design and analysis of bridging and multiregional clinical trials.
    Tsong Y; Wang W
    J Biopharm Stat; 2012 Sep; 22(5):875-8. PubMed ID: 22946936
    [No Abstract]   [Full Text] [Related]  

  • 12. Multiregional clinical trials: Japanese perspective on drug development strategy and sample size for Japanese subjects.
    Ando Y; Uyama Y
    J Biopharm Stat; 2012 Sep; 22(5):977-87. PubMed ID: 22946944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal designs in longitudinal trials with varying treatment effects and discrete-time survival endpoints.
    Safarkhani M; Moerbeek M
    Stat Med; 2015 Sep; 34(22):3060-74. PubMed ID: 26179808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statistical design of noninferiority multiple region clinical trials to assess global and consistent treatment effects.
    Diao G; Zeng D; Ibrahim JG; Rong A; Lee O; Zhang K; Chen Q
    J Biopharm Stat; 2017; 27(6):933-944. PubMed ID: 28296570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinician as investigator: participating in clinical trials in the practice setting: Appendix 2: statistical concepts in study design and analysis.
    Lader EW; Cannon CP; Ohman EM; Newby LK; Sulmasy DP; Barst RJ; Fair JM; Flather M; Freedman JE; Frye RL; Hand MM; Jesse RL; Van de Werf F; Costa F;
    Circulation; 2004 Jun; 109(21):e305-7. PubMed ID: 15173053
    [No Abstract]   [Full Text] [Related]  

  • 16. Analyzing randomized dose finding studies with a primary and a secondary endpoint.
    Hothorn LA; Wassmer G
    J Biopharm Stat; 2003 May; 13(2):301-5. PubMed ID: 12729396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hybridization of conditional and predictive power for futility assessment in sequential clinical trials with time-to-event outcomes: a resampling approach.
    Yi J; Fang L; Su Z
    Contemp Clin Trials; 2012 Jan; 33(1):138-42. PubMed ID: 21983624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration.
    Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
    J Clin Psychiatry; 2012 Jun; 73(6):856-64. PubMed ID: 22687813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Applying the law of iterated logarithm to control type I error in cumulative meta-analysis of binary outcomes.
    Hu M; Cappelleri JC; Lan KK
    Clin Trials; 2007; 4(4):329-40. PubMed ID: 17848494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of vaccine equivalence/non-inferiority trials with correlated multiple binomial endpoints.
    Kong L; Kohberger RC; Koch GG
    J Biopharm Stat; 2006; 16(4):555-72. PubMed ID: 16892913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.